Amgen (AMGN) Stock Surges 4% on Breakthrough Sjögren’s Disease Trial Results
Key Highlights Shares of Amgen rose approximately 4% during premarket hours Tuesday following encouraging Phase 3 data for dazodalibep in treating Sjögren’s disease The OASIZ 301 clinical tri


